Nosso principal objetivo é elaborar " PROTOCOLOS DE CONSENSO " das estratégias terapêuticas, com a finalidade de " REGULAMENTAÇÃO " no Conselho Federal de Medicina ou nos Conselhos de Classe Competentes.

Referências Bibliográficas

 

  1. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med; 162: 1286 – 1292, 2002.
  2. Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension; 39: 197 – 202, 2002.
  3. Ajani UA, Ford ES, Mokdad AH. Dietary fiber and C-reactive protein: findings from national health and nutrition examination survey data. J Nutr; 134: 1181 – 1185, 2004.
  4. Ajwani S, Mattila KJ, Narhi TO, Tilvis RS, Ainamo A. Oral health status, C-reactive protein and mortality – a 10 years follow-up study. Gerodontology; 20: 32 – 40, 2003.
  5. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation; 105: 2595 – 2599, 2002.
  6. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women’s Health Study). Am J Cardiol; 93: 1238 – 1242, 2004.
  7. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation; 107: 443 – 447, 2003.
  8. Alexandrakis MG, Passam FH, Ganotakis ES, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol; 25: 41 – 46, 2003.
  9. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail; 4: 331 – 336, 2002.
  10. Alpert PT. New and Emerging Theories of Cardiovascular Disease: Infection and Elevated Iron. BIOLOGICAL RESEARCH FOR NURSING, 6(1): 3 – 10, 2004.
  11. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg; 38: 1018 – 1024, 2003.
  12. Amar S, Gokce N, Morgan S, Loukideli M, Van Dyke TE, Vita JA. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. Arterioscler Thromb Vasc Biol; 23: 1245 – 1249, 2003.
  13. Anand SS, Razak F, Yi Q, et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Tromb Vasc Biol; 24: 1509 – 1515, 2004.
  14. Arenillas JF, Alvarez-Sabin J, Molina CA, et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke; 34: 2463 – 2468, 2003.
  15. Arnalich F, Hernanz A, Lopez-Maderuelo D, et al. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm Metab Res; 32: 407 – 412, 2000.
  16. Aronson D, Bartha P, Zinder O, et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med; 21:39 – 44, 2004.
  17. Asselbergs FW, van Boven AJ, Stuveling EM, et al. Relation of electrocardiographic abnormalities to levels of serum C-reactive protein. Am J Cardiol; 91: 1358 – 1360, 2003.
  18. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation; 108: 3006 – 3010, 2003.
  19. Baer DJ, Judd JT, Clevidence BA, Tracy RP. Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. Am J Clin Nutr; 79: 969 – 973, 2004.
  20. Balagopal P, George D, Yarandi H, Funanage V, Bayne E. Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: A controlled, randomized study in obese adolescents. The Journal of Clinical Endocrinology & Metabolism, 90(11): 6192 – 6197, 2004.
  21. Balagopal P, George D, Patton N, Yarandi H, Roberts WL, Bayne E, Gidding S. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents. J Pediatr, 146(3): 342 – 8, 2005a.
  22. Balagopal P, George D, Yarandi H, Funanage V, Bayne E. Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents. J Clin Endocrinol Metab, 90(11): 6192 – 7, 2005b.
  23. Ballou SP, Lozanski FB, Hodder S, et al. Quantitative and qualitative alterations of acute-phase proteins in health elderly persons. Age Ageing; 25: 224 – 230, 1996.
  24. Bank AJ, Billups KL, Kaiser DR , et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res; 15: 231 – 236, 2003.
  25. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health study. Diabetes; 50: 2384 – 2389, 2001.
  26. Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation; 99: 2219 – 2222, 1999.
  27. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens; 19: 857 – 861, 2001.
  28. Becker OR. Electromagnetism and the revolution in medicine. Acupunct Electrother Res, 12: 75 – 9, 1987.
  29. Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res; 43: 529 – 534, 1997.
  30. Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-reactive protein in acute myocardial infarction: Association with heart failure. Am Heart J; 145: 1094 – 1101, 2003.
  31. Bholasingh R, Cornel JH, Kamp O, et al. The prognostic value of markers of inflammation in patients with troponin T-negative chest pain before discharge from the emergency department. Am J Med; 115: 521 – 528, 2003.
  32. Biancari F, Lahtinen J, Lepojarvi S, et al. Preoperative C-reactive protein and outcome after coronary artery bypass surgery. Ann Thorac Surg; 76: 2007 – 2012, 2003.
  33. Bickel C, Rupprecht HJ, Blankenberg S, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen,von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol; 89: 901 -908, 2002.
  34. Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol; 21: 1962 – 1968, 2001.
  35. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation; 108: 2993 – 2999, 2003.
  36. Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol; 24: 372 – 376, 1997.
  37. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and psysical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci; 59: 242 – 248, 2004.
  38. Chambers JC, Eda S, Bassett P, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation; 104: 145 – 150, 2001.
  39. Chamdalia M, Cabo-Chan AV Jr, Devaraj S, Jialal I, Grundy SM, Abate N. Elevated plasma high-sensitivity C-reactve protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab; 88: 3773 – 3776, 2003.
  40. Chang CY, Chen JY, Ke D, Hu ML. Plasma levels of lipophilic antioxidant vitamins in acute ischemic stroke patients: correlation to inflammation markers and neurological deficits. Nutrition, 21(10): 987 – 93, 2005.
  41. Chase HP, Cooper S, Osberg I, et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes; 53: 2569 – 2573, 2004.
  42. Chen J, Wildman RP, Hamm LL, Muntner P, Reynolds K, Whelton PK , He J, Third National Health and Nutrition Examination Survey. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care, 27(12): 2960 - 5, 2004.
  43. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. Effects of chronic alcohol consumption on lipid levels, inflammatory and haemostatic factors in the general population: the “ ATTICA ” Study. J Cardiovasc Risk; 10: 355 – 361, 2003.
  44. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension satatus and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens; 17: 568 – 573, 2004.
  45. Chul Sung K, Suh JY, Kim BS, et al. High-sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens; 16: 429 – 433, 2003.
  46. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation; 104: 2886 – 2891, 2001.
  47. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol; 22: 1869 – 1876, 2002.
  48. Clifton PM. Diet and C-reactive protein. Curr Atheroscler Rep; 5: 431 – 436, 2003.
  49. Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol; 93: 1368 – 1373, 2004.
  50. Cossariza A, et al: Extremely low frequency pulsed electromagnetic fields increase cell proliferation in lymphoytes from young and aged subjects. Biochem Biophys Res Commun, 160(2): 692 – 8, 1989a.
  51. Cossariza A, et al: DNA repair after gama irradiation in lymphocytes exposed to low- frequency pulsed electromagnetic fields. Radiation Research (118): 161 – 68, 1989b.
  52. Couillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P, Lamarche B, Bergeron N. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab, 90(12): 6454 – 9, 2005.
  53. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen / Progestin Interventions (PEPI) Study. Circulation; 100: 717 – 722, 1999.
  54. Dalton RR, Hoffman WH, Passmore GG, Martin SL. Plasma C-reactive protein levels in severe diabetic ketoacidosis. Ann Clin Lab Sci; 33: 435 – 442, 2003.
  55. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective base don interactions between obesity, diabetes, and inflammation. Circulation, 111(11): 1448 – 54, 2005.
  56. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med; 65: 347 – 356, 2003.
  57. Das I, Raised C-reactive protein levels in serum from smokers. Clin Chim Acta; 153: 9 – 13, 1985.
  58. de Winter RJ, Koch KT, van Straalen JP, et al. C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med; 115: 85 – 90, 2003.
  59. deFilippi C, Wasserman S, Rosanio S, et al.Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA; 290: 353 – 359, 2003.
  60. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol; 56: 375 – 380, 2001.
  61. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke; 32: 917 – 924, 2001.
  62. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke; 32: 133 – 138, 2001.
  63. Donaldson K, Stone V, Seaton A, MacNee W. Ambient particle inhalation and the cardiovascular system: potential mechanisms. Environ Health Perspect; 109(Suppl 4): 523 – 527, 2001.
  64. Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci; 73: 1245 – 1252, 2003.
  65. Ehlermann P, Mirau W, Jahn J, Remppis A, Sheikhzadeh A. Predictive value of inflammatory and hemostatic parameters, atherosclerotic risk factors, and chest X-ray for aortic arch atheromatosis. Stroke; 35: 34 – 39, 2004.
  66. Elahi MM, McMillan DC , McArdle CS, Argerson WJ, Sattar N. Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer; 48: 171 – 173, 2004.
  67. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol; 61: 668 – 672, 2004.
  68. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA; 291: 585 – 590, 2004.
  69. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA, 292: 1440 – 1446, 2004.
  70. Feldman EB. The scientific evidence for a beneficial health relationship between walnuts and coronary heart disease. J Nutr, 132: 1062S – 1101S, 2002.
  71. Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr; 32: 210 – 214, 2003.
  72. Felippe J Jr. Radicais Livres como Mecanismo Intermediário de Moléstia. In Felippe J Jr. Pronto Socorro: Fisiopatologia – Diagnóstico – Tratamento. Ed.Guanabara – Koogan. 1168 – 1173, 1990.
  73. Felippe J Jr. Medicina Biomolecular. Revista Brasileira de Medicina Biomolecular e radicais Livres. 1(1): 6 7, 1994 e www.medicinacomplementar.com.br
  74. Felippe J Jr. Tratamento de doenças envolvendo freqüências de ondas. Journal of Biomolecular Medicine & Free Radicals, 6(2): 39 – 40, 2000a. www.medicinacomplementar.com.br
  75. Felippe J Jr. Bioeletromagnetismo: Medicina Biofísica. Journal of biomolecular medicine & Free Radicals, 6(2): 41 – 44,2000b.
  76. Felippe J Jr. Oscilador de Mústiplas Ondas de Lakhovisky – casos Clínicos. Journal of Biomolecular Medicine & Free Radicals, 6(2): 37, 2000c. www.medicinacomplementar.com.br
  77. Felippe J Jr. Georges Lakhovisky: Efeitos das Ciências Físicas na Biologia. Journal of Biomolecular Medicine& Free radicals, 6(1): 16 – 21, 2000d.
  78. Felippe J Jr. Estratégia Biomolecular: uma das Bases da Medicina do Futuro. Revista Brasileira de Medicina Complementar, 7(1): 8 – 9, 2001.
  79. Fernadez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab; 86: 1154 – 1159, 2001.
  80. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation; 102: 42 – 47, 2000a.
  81. Festa A, D’Agostino R, Hales CN, Mykkien L, Haffner SM. Heart rate in relation to insulin sensivity and insulin secretion in nondiabetic subjects. Diabetes Care, 23(5): 624 – 8, 2000b.
  82. Festa A, D’Agostino R, Howard G, Mykkien L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int, 58(4): 1703 – 10, 2000c.
  83. Festa A, D’Agostino R, Tracy RP, Haffner SM. C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjetcts; the Insulin Resistance Atherosclerosis Study. Diabet Med; 19: 939 – 943, 2002.
  84. Fialová L, Kalousová M, Soukupová J, Malbohan I, Madar J, frisová V, Stipek S, Zima T. Markers of inflammation in preeclampsia. Prague Med Rep, 105(3): 301 – 10, 2004.
  85. Fink JC, Onuigbo MA, Blahut SA, et al. Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. Am J Kidney Dis; 39: 1096 – 1101, 2002.
  86. Fischer G, Sametz W, Juan H. Influence of a magnetic field on the development of the carrageenan-induced rat paw oedema. Med Klin, 82(17): 566 – 570, 1987.
  87. Fischer CP, Hiscock NJ, Penkowa M, Basu S, Vessby B, Kallner A, Sjöberg LB, Pedersen BK. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol, 558(Pt 2): 633-45, 2004.
  88. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. Hyperinsulinemia provokes synchronous increase in central inflammation and beta-amyloid in normal adults. Arch Neurol, 62(10): 1539 – 44, 2005.
  89. Fleming RM. The effect of high-protein diets on coronary blood flow. Angiology;51: 817 – 826, 2000.
  90. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care; 22: 1971 – 1977, 1999
  91. Ford ES, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH. C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988 – 1994. J Pediatr, 138(4): 486 – 92, 2001.
  92. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology; 13: 561 – 568, 2002.
  93. Ford ES, Giles WH, Myers GL, Mannino DM. Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. Clin Chem; 49:686 – 690, 2003a.
  94. Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino DM. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem; 49: 1353 – 1357, 2003b.
  95. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis, 168(2): 351 – 8, 2003c.
  96. Ford DE , Erlinger TP. Depression and C-reactive protein in US adults: data from the third national health and nutrition examination survey. Arch Intern Med; 164: 1010 – 1014, 2004.
  97. Ford ES, Mokdad AH, Liu S. Healthy Eating Index and C-reactive protein concentration: findings from the National Health and Nutrition Examination Survey III, 1988 – 1994. Eur J Clin Nutr, 59(2): 278 – 83, 2005.
  98. Fredriksson MI, Figueredo CM, Gustafsson A, Bergstrom KG, Asman BE. Effect of periodontitis and smoking on blood leukocytes and acute-phase proteins. J Periodontol; 70: 1355 – 1360, 1999.
  99. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes; 51: 1596 – 1600, 2002.
  100. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care; 23: 1835 – 1839, 2000.
  101. Frohlich M, Sund M, Lowel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J; 24: 1365 – 1372, 2003.
  102. Galloway P, McMillan DC , Sattar N. Effect of the inflammatory response on trace element and vitamin status. Ann Clin Biochem, 37: 289 – 297, 2000.
  103. Galloway PJ, Thomson GA, Fischer BM, Semple CG. Insulin-induced hypoglycemia induces a rise in C-reactive protein. Diabetes Care; 23: 861 – 862, 2000.
  104. Gao X, Bermudez OI, Tucker KL. Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders. J Nutr; 134: 913 – 918, 2004.
  105. Garcia-Moll X, Zouridakis E, Cole D, Kaski JC. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J; 21: 1598 – 1606, 2000.
  106. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol; 153: 242 – 250, 2001.
  107. Gerber IL , Stewart RA, Hammett CJ, et al. Effect of aortic valve replacement on C-reactive protein in nonrheumatic aortic stenosis. Am J Cardiol; 92: 1129 – 1132, 2003.
  108. Golbasi Z, Ucar O, Keles T, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart fail; 4: 593 – 595, 2002.
  109. Goodman R, et al: Exposure of human cells to low-frequency electromagnetic fields results in quantitative changes in transcripts. Biochim Biophis Acta, 1009(3): 216 – 20, 1989.
  110. Gottdiener JS, Arnaold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol; 35: 1628 – 1637, 2000.
  111. Greer RM, Buntain HM, Lewindon PJ, Wainwright CE, Potter JM, Wong JC, Francis PW, Batch JA, Bell SC. Vitamin A levels in patients with CF are influenced by the inflammatory response. J Cyst Fibros, 3(3): 143 – 9, 2004.
  112. Grimble RF. Inflammatory status and insulin resistence. Curr Opin Clin Nutr Metab Care; 5: 551 – 559, 2002.
  113. Grundy SM. Inflammation, metabolic syndrome, and diet responsiveness. Circulation; 108: 126 – 128, 2003.
  114. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E, Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes, 54(5): 1566 – 72, 2005.
  115. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study. Diabetes Care; 25: 2016 – 2021, 2002.
  116. Hansen TK, Thiel S, Knudsen ST , et al. Elevated levels of mannanbinding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab; 88: 4857 – 4861, 2003.
  117. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger Jr WH, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med, 106: 506 – 512, 1999.
  118. Hartmann G, Tschop M, Fischer R, et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine; 12: 246 – 252, 2000.
  119. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation; 104: 63 – 67, 2001.
  120. Heald AH, Anderson SG, Ivison F, Laing I, Gibson JM, Cruickshank K. C-reactive protein and the insulin-like growth factor (IGF)-system in relation risk of cardiovascular disease in different ethnic groups. Atherosclerosis; 170: 79 – 86, 2003.
  121. Hegele RA, Ban MR, Young TK. Serum C-reactive protein in Canadian Inuit and its association with genetic variation on chromosome 1 q21. Clin Chem; 47: 1707 – 1709, 2001.
  122. Heitritter SM, Solomon CG, Mitchell G, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with prior gestational diabetes mellitus. J Clin Endocrinol Metab; 90: 3983 – 3988, 2005.
  123. Hemingway H, Shipley M, Mullen MJ, et al. Social and psychosocial influences on inflammatory markers and vascular function in civil servants (the Whitehall II study). Am J Cardiol; 92: 984 – 987, 2003.
  124. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke; 36: 768 – 772, 2005.
  125. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes; 53: 693 – 700, 2004.
  126. Huhtinen M, Repo H, Laasila K, et al. Systemic inflammation and innate immune response in patients with previous anterior uveitis. Br J Ophthalmol; 86: 412 – 417, 2002.
  127. Hutchinson , W.L., et al. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin. Chem, 46: 934 – 938, 2000.
  128. Hvilsom GB, Thorsen P, Jeune B, Bakketeig LS. C-reactive protein: a serological marker for preterm delivery? Acta Obstet Gynecol Scand; 81: 424 – 429, 2002.
  129. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host-and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg; 238: 197 – 202, 2003.
  130. Imhof A, Froehlich M, Brenner H, Boening H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet; 357: 763 – 767, 2001.
  131. Imhof A, Frohlich M, Loewel H, et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem; 49: 669 – 672, 2003.
  132. Isasi CR, Deckelbaum RJ, Tracy RP, Starc TJ, Berglund L, Shea S. Physical fitness and C-reactive protein level in children and young adults: the Columbia University BioMarkers Study. Pediatrics; 111: 332 – 338, 2003.
  133. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant; 14: 1956 -1960, 1999.
  134. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol; 91: 287 – 292, 2003.
  135. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and non-diabetic subjects: the Hoorn study. Arterioscler Thromb Vasc Biol; 19: 3071 – 3078, 1999.
  136. Jager A, van Hinsbergh VW, Kostense PJ, et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol; 22: 593 – 598, 2002.
  137. James S, Wallentin L. C-reactive protein provides independent prognostic information on short-and long-term mortality in patients with non-st elevation acute coronary syndrome: reply. J Am Coll Cardiol; 42: 1145 – 1146, 2003.
  138. Jeong WK, Jeong MH, Kim KH, et al. An elevated value of C-reacive protein is the only predictive factor of restenosis after percutaneous coronary intervention. Korean J Intern Med; 18: 154 – 160, 2003.
  139. Johnson MT, Waite LR, Nindl G. Noninvasive treatment of inflammation using electromagnetic fields: current and emerging therapeutic potential. Biomed Sci Instrum, 40: 469 – 74, 2004.
  140. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med; 112: 275 – 280, 2002.
  141. Joshipura KJ, Wand HC, Merchant AT, Rimm EB. Periodontal disease and biomarkers related to cardiovascular disease. J Dent Res; 83: 151 – 155, 2004.
  142. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. Association of markers of systemic inflammation, C-reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J Epidemiol Community Health; 57: 730 – 733, 2003.
  143. Jublanc C, Bruckert E, Giral P, et al. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis; 172: 7 – 11, 2004.
  144. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. C-reactive protein in Young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism; 52: 1113 – 1116, 2003.
  145. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab; 86: 2453 – 2455, 2001.
  146. Kilpatrick ES, Keevil BG, Jagger C, Spooner RJ, Small M. Determinants of raised C-reactive protein concentration in type 1 diabetes. QJM; 93: 231 – 236, 2000.
  147. King DE , Mainous AG 3 rd, Pearson WS. C-reactive protein, diabetes, and attendance at religious services. Diabetes care; 25: 1172 – 1176, 2002.
  148. King DE , Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol; 92: 1335 – 1339, 2003.
  149. Klebl FH, Bregenzer N, Rogler G, Straub RH, Schimerich J, Andus T. Treatment of pouchitis with dehydroepiandrosterone (DHEA) – a case report. Z Gastroenterol, 41(11): 1087 – 90, 2003.
  150. Kluft C, de Maat MPM. Genetics of C-reactive protein: new possibilities and complications. Arterioscler Tromb Vasc Biol; 23: 1956 – 1959, 2003.
  151. Koening W, Sund M, Frilich M, Fischer HG, Liel H, Diing A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 99(2): 237 – 42, 1999.
  152. Koh JM, Khang YH, Jung CH, et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int; 16: 1263 – 1271, 2005.
  153. Kop WJ, Gottdiener JS, Tangen CM, et al. Inflammation and coagulation factors in persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol; 89: 419 – 424, 2002.
  154. Krabble KS , Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol, 39(5): 687 – 99, 2004.
  155. Krasuski RA, Bush A, Kay JE, et al. C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy. Am heart J; 146: 1099 – 1104, 2003.
  156. Kritchevsky SB, Bush AJ, Pahor M, Gross MD. Serum carotenoids and markers of inflammation in nonsmokers. Am J Epidemiol, 152: 1065 – 1071, 2000.
  157. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol; 4: 371 – 380, 2005.
  158. Kushner I, Rzewnicki D, Samols D. What Does Minor Elevation Of C-Reactive Protein Signify? The American Journal of Medicine; 119, 166.e17 – 166.e28, 2006.
  159. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol, 149(6): 601 – 8, 2003.
  160. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology; 22: 370 – 379, 2000.
  161. Lavedrine F, Zmirou D, Ravel A, Balducci F, Alary J. Blood cholesterol and walnut consumption: a cross-sectional survey in France . Prev Med, 28: 333 – 339, 1999.
  162. Licastro F, Chiappelli M, Ruscica M, Carnelli V, Corsi MM. Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer’s type. Int J Immunopathol Pharmacol; 18: 165 – 172, 2005.
  163. Lind P, Hedblad B, Stavenow L, Engström G, Janzon L, Ogren M, Lindgärde F. Incidence of myocardial infarction and relation to walking-induced calf pain and plasma levels of inflammation-sensitive proteins. Angiology, 56(5): 507-16, 2005.
  164. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr; 75: 492 – 498, 2002.
  165. Lobo SMA, Lobo FRM, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest; 123: 2043 – 2049, 2003.
  166. Lopez-Garcia E, Schulze MB , Fung TT, et al. Major dietary patterns are related to plasma concentrations of markers in inflammation and endothelial dysfunction. Am J Clin Nutr; 80: 1029 – 1035, 2004.
  167. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of transfatty acids is related is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr; 135: 562 – 566, 2005.
  168. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol, 23: 1255 – 1261, 2003.
  169. Lushnikov KV, Shumilina YV, Yakushina VS, Gapeev AB , Sadovnikov VB, Chemeris NK. Effects of low- intensity ultrahigh frequency electromagnetic radiation on inflammatory processes. Bull Exp Biol Med, 137(4): 364 – 6, 2004.
  170. Lyon CJ, Law RE, Hsueh WA . Minireview: adiposity, inflammation, and atherogenesis. Endocrinology; 144: 2195 – 2200, 2003.
  171. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem; 43: 52 – 58, 1997.
  172. Mangoni ED, Adinolfi LE, Tripodi MF, et al. Risk factors for “major” embolic events in hospitalized patients with infective endocarditis. Am Heart J; 146: 311 – 316, 2003.
  173. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med; 114: 758 – 762, 2003.
  174. Manns PJ, Williams DP, Snow CM, Wander RC. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Am J Human Biol; 15: 91 – 100, 2003.
  175. Marfella R, Siniscalchi M, Esposito K, et al. Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care; 26: 3129 – 3135, 2003.
  176. Margaglione M, Cappucci G, Colaizzo D, Vecchione G, Grandone E, Di Minno G. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives.. Arterioscler Thromb Vasc Biol; 20: 198 – 203, 2000.
  177. Masi AT, Aldag JC, Sipes J. Do elevated levels of serum C-reactive protein predict rheumatoid arthritis in men: correlations with pre-RA status and baseline positive rheumatoid factors. J Rheumatol; 28: 2359 – 2361, 2001.
  178. Matsumoto K, Sera Y, Abe Y, Ueki Y, Tominaga T, Miyake S. Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. Atherosclerosis; 169: 317 – 321, 2003.
  179. Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med; 21: 21 – 24, 2000.
  180. McConnell JP, Branum EL, Ballman KV, Lagerstedt SA, Katzmann JA, Jafee AS. Gender differences in C-reactive protein concentrations-confirmation with two sensitive methods. Clin Chem Lab Med; 40: 56 -59, 2002.
  181. McMillan DC, Sattar N, Talwar D, O’Reilly DS, McArdle CS. Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer. Nutrition, 16: 425 – 428, 2000.
  182. McMillan CD, Talwar D, Sattar N, Underwood M, O’Reilly DS, McArdle C. The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumours. Clinical Nutrition, 21(2): 161 – 164, 2002.
  183. McMillan DC , Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg; 90: 215 – 219, 2003.
  184. McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation; 106: 2908 – 2912, 2002.
  185. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J; 21: 1584 – 1590, 2000.
  186. Merlini G, Perfetti V, Gobbi PG, et al. Acute phase proteins and prognosis in multiple myeloma. Br J Haematol; 83: 595 – 601, 1993.
  187. Messerli AW, Seshadri N, Pearce GL, Sachar R, Hoogwerf BJ, Sprecher DL. Relation of albumin/creatinine ratio to C-reactive protein and to the metabolic syndrome. Am J Cardiol; 92: 610 – 612, 2003.
  188. Meydani M. A Mediterranean-style diet and metabolic syndrome. Nutrition Reviews, 63(9): 312 – 314, 2005.
  189. Milionis HJ, Mittari V, Exarchakos G, Kalaitzidis R, Skevas AT, Elisaf MS. Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis. Eur J Clin Invest; 33: 1045 – 1050, 2003.
  190. Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC. Trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr, 80(6): 1521 – 5, 2004a.
  191. Mozaffarian D, Pischon T, Hankinson SE, Rifai N, Joshipura K, Willett WC, Rimm EB. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr, 79(4): 606 – 12, 2004b.
  192. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese americans. Diabetes Care; 26: 2754 – 2757, 2003.
  193. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis; 42: 53 – 61, 2003.
  194. Newman AB , Arnold AM, Naydeck BL, et al. “Successful aging”: affect of subclinical cardiovascular disease. Arch Intern Med; 163: 2315 – 2322, 2003.
  195. Nielen MM, van Schaardenburg D, Reesink HW, et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum; 50: 2423 – 2427, 2004.
  196. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol; 72: 1221 – 1227, 2001.
  197. Noh H, Lee SW, Kang SW, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int; 18: 387 – 394, 1998.
  198. Oshima T, Ozono R, Yano Y, et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol; 45: 1219 – 1222, 2005.
  199. Owen N, Poulton T, Hay FC, Mohamed-Ali V, Steptoe A. Socioeconomic status, C-reactive protein, immune factors, and responses to acute mental stress. Brain Behav Immun; 17: 286 – 295, 2003.
  200. Palmieri V, Tracy RP, Roman MJ, et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care; 26: 2764 – 2769, 2003.
  201. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis; 154: 681 – 689, 2001.
  202. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C-reactive protein is independetly associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord; 25: 1416 – 1420, 2001.
  203. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect os C-reactive protein on human endothelial cells. Circulation, 102(18): 2165 – 8, 2000.
  204. Peden DB. Pollutants and asthma: role of air toxics. Environ Health Perspect, 110(4): 565 – 8, 2002.
  205. Pedersen LM, Bergmann OJ. Urinary albumin excretion and its relationship to C-reactive protein and proinflammatory cytokines in patients with cancer and febrile neutropenia. Scand J Infect Dis; 35: 491 – 494, 2003.
  206. Pennix BW, Kritchevsky SB, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol Psychiatry; 54: 566 – 572, 2003.
  207. Pepys, M.B., and Baltz, ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol, 34: 141 – 212, 1983.
  208. Peters A, Frohlich M, Doring A, et al. Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J; 22: 1198 – 1204, 2001.
  209. Pihl E, Zilmer K, Kullisaar T, Kairane C, Pulges A, Zilmer M. High-sensitive C-reactive protein level and oxidative stress-related status in former athletes in relation to traditional cardiovascular risk factors. Atherosclerosis; 171: 321 – 326, 2003.
  210. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rimm EB. Leisure-time physical activity and reduced plasma levels of obesity related inflammatory markers. Obes Res; 11: 1055 – 1064, 2003.
  211. Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev, 13(2): 279 – 84, 2004.
  212. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in non-diabetic women. Arterioscler Thromb Vasc Biol; 23: 650 – 655, 2003.
  213. Price JA, Strattan RD. Analysis of the effect of a 60 Hz AC field on histamine release by rat peritoneal mast cells. Bioelectromagnetics, 19(3): 192 – 8, 1998.
  214. Qiu C, Luthy DA, Zhang C, Walsh SW, Leisenring WN, Williams MA. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. Am J Hypertens; 17: 154 – 160, 2004.
  215. Rahel BM, Visseren FL, Suttorp MJ, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Resc; 60: 136 – 140, 2003.
  216. Ravaglia G, Forti P, Maioli F, Brunetti N, Martelli M, Talerico T, Bastagli L, Muscari A, Mariani E. Peripheral blood markers of inflammation and function impairment in elderly community-dwellers. Exp Gerontol, 39(9): 1415 – 22, 2004.
  217. Rawson ES, Freedson PS, Osganian SK, Matthews CE, Reed G, Ockene IS. Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc; 35: 1160 – 1166, 2003.
  218. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol; 13: 674 – 682, 2003.
  219. Ridker PM. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation; 105: 2583 – 2585, 2002.
  220. Riese H, Vrijkotte TG, Meijer P, Kluft C, De Geus EJ. Diagnostic strategies for C-reactive protein. BMC Cardiovasc Disord; 2: 9, 2002.
  221. Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States : implication for clinical interpretation. Clin Chem; 49: 666 – 669, 2003.
  222. Romano M, Guagnano MT, Pacini G, et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab; 88: 5321 – 5326, 2003.
  223. Rost NS , Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke; 32: 2575 – 2579, 2001.
  224. Rothenbacher D, Hoffmeister A, Brenner H, Koening W. Physical activity, coronary heart disease, and inflammatory response. Arch Intern Med; 163: 1200 – 1205, 2003.
  225. Ruhenstroth-Bauer G, Rösing O, Baumer H, Sönning W, Lehmacher W. Demonstration of correlations between the 8 and 10 kHz atmospherics and the inflammatory reaction of rats after carrageenan injection. Int J Biometeorol, 32(3): 201 – 4, 1988.
  226. Sabatine MS, Morrow DA, Cannon CP,et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes. A TACTICS-TIMI 18 substudy. J Am Coll Cardiol; 40: 1761 – 1768, 2002.
  227. Sacks GP, Seyani L, Lavery S, Trew G. Maternal C-reactive protein levels are raised at 4 weeks gestation. Hum Reprod; 19: 1025 – 1030, 2004.
  228. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J; 25: 363 – 370, 2004.
  229. Sampietro T, Bigazzi F, Dal Pino B, et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? Circulation; 105: 11 – 14, 2002.
  230. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia; 46: 1402 – 1407, 2003.
  231. Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol; 22: 811 – 813, 1999.
  232. Sattar N, McConnachie A, O’Reilly D, et al. Inverse association between birth weight and C-reactive protein concentrations in the MIDSPAN Family Study. Arterioscler Thromb Vasc Biol; 24: 583 – 587, 2004.
  233. Schaumberg DA, Ridker PM, Glynn RJ, Christen WG, Dana MR, Hennekens CH. High levels of plasma C-reactive protein and future risk of age-related cataract. Ann Epidemiol; 9: 166 – 171, 1999.
  234. Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens; 21: 1841 – 1846, 2003.
  235. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25 year follow-up of the Honolulu-Asia Aging Study. Ann Neurol; 52: 168 – 174, 2002.
  236. Schulze MB, Hoffmann K, Manson JE, Willett WC, meigs JB, Weikert C, Heidemann C, Colditz GA, Hu FB. Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr, 82(3): 675 – 84; quiz 714 – 5 , 2005.
  237. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA; 291: 704 – 710, 2004.
  238. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Krichner H. Cytokine production and serum proteins in depression. Scand J Immunol; 41: 534 – 538, 1995.
  239. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States : results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation; 110: 738 – 743, 2004.
  240. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA; 290: 2945 – 2951, 2003.
  241. Shai I, Rimm EB, Schulze MB, Rifai N, Stampfer MJ, Hu FB. Moderate alcohol intake and markers of inflammation and endothelial dysfunction among diabetic men. Diabetologia, 47(10): 1760 – 7, 2004.
  242. Shamsuzzaman AS , Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation; 105: 2462 – 2464, 2002.
  243. Shimada H, Nabeya Y, Okazumi S, et al. Elevation of preoperative serum C-reactive protein levels is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol; 83: 248 – 252, 2003.
  244. Shine, B., de Beer, F.C., and Pepys, M.B. Solid phase radioimmunoassay for C-reactive protein. Clin. Chim. Acta, 117: 13 – 23, 1981.
  245. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation; 107: 3165 – 3169, 2003.
  246. Sites CK, Toth MJ, Cushman M, L’Hommedieu GD, Tchernof A, Tracy RP, Poehlman ET. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril, 77(1): 128 – 35, 2002.
  247. Sitzer M, Markus HS, Mendall MA, Liehr R, Knorr U, Steinmetz H. C-reactive protein and carotid intimal medial thickness in a community population. J Cardiovasc Risk; 9: 97 – 103, 2002.
  248. Slade GD, Ghezzi EM, Heiss G, Beck JD, Riche E, Offenbacher S. Relationship between periodontal disease and C-reactive protein among adults in the atherosclerosis risk in communities study. Arch Intern Med; 163: 1172 – 1179, 2003.
  249. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology; 35: 123 – 127, 1997.
  250. Smith JK, Dyles R, Douglas JE, Krishnaswamy G, Berk S. Longterm exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease.JAMA; 281: 1722 – 1727, 1999.
  251. Soop M, Duxbury H, Agwunobi AO, Gibson JM, Hopkins SJ, Childs C, Cooper RG, maycock P, Little RA, Carlson GL. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab, 282(6): E1276 – 85, 2002.
  252. Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Ostheoarthritis Cartilage; 10: 595 – 601, 2002.
  253. Sowers MR, Jannausch M, Randolph JF, McConnell D, Little R, Lasley B, Pasternak R, Sutton-Tyrrell K, Matthews KA. Androgens are associated with hemostatic and inflammatory factors among women at the mid-life. J Clin Endocrinol Metab, 90(11): 6064 – 71, 2005.
  254. Spector TD, Hart DJ, Nandra D, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum; 40: 723 – 727, 1997.
  255. Straub RH, Lehle K, Herfarth H, Weber M, Falk W, Preuner J, Scholmerich J. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor. Eur J Endocrinol, 146(3): 365 – 74, 2002.
  256. Stewart SH, Mainous AG 3rd, Gilbert G. Relation between alcohol consumption and C-reactive protein levels in the adult US population. J Am Board Fam Pract; 15: 437 – 442, 2002.
  257. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol; 20: 1057 – 1060, 2000.
  258. Straub RH, Vogl D, Gross V, Lang B, Schimerich J, Andus T. Association of humoral markers inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol, 93(11): 2197 – 202, 1998a.
  259. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Schimerich J, Falk W, Lang B. Serum dehydroepiandrosterone (DHEA) and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab, 83(6): 2012 – 7, 1998b.
  260. Straub RH, Schimerich J, Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases-substitutes of adrenal and sex hormones. Z Rheumatol, 59 Suppl 2: II/ 108 - 18, 2000.
  261. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int; 63: 654 – 661, 2003.
  262. Stuveling EM, Bakker SJ, Hillege HL, et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension; 43: 791 – 796, 2004.
  263. Sugimori K, Kawaguchi Y, Morita M, Kitajima I, Kimura T. High-sensitivity analysis of serum C-reactive protein in young patients with lumbar disc herniation. J Bone Joint Surg Br; 85: 1151 – 1154, 2003.
  264. Suleiman M, Aronson D, Reisner SA, et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med; 115: 695 – 701, 2003.
  265. Talwar D, Ha TK, Scott HR, Cooney J, Fell GS, O’Reilly DS, Lean ME, McMillan DC . Effect of inflammation on measures of antioxidant status in patients with non-small cell lung cancer. Am J Clin Nutr, 66: 1283 – 1285, 1997.
  266. Tamakoshi K, Yatsuya H, Kondo T, et al. Long-term body weight variability is associated with elevated C-reactive protein independent of current body mass index among Japanese men. Int J Obes Relat Metab Disord; 27: 1059 – 1065, 2003.
  267. Tamakoshi K, Yatsuya H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord; 27: 443 – 449, 2003.
  268. Tan KC, Wat NM, Tam SC, Janus ED, Lam TH, Lam KS . C-reactive protein predicts the deterioration of glycemia in chinese subjects with impaired glucose tolerance. Diabetes Care; 26: 2323 – 2328, 2003.
  269. Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism; 51: 743 – 749, 2002.
  270. Teppo AM, Tornroth T, Honkanen E, Gronhagen-Riska C. Elevated serum C-reactive protein associates with deterioration of renal function in transplant recipients. Clin Nephrol; 60: 248 – 256, 2003.
  271. Teunissen CE, van Boxtel MP, Bosma H, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol; 134: 142 – 150, 2003.
  272. Tjoa ML, van Vugt JM, Go AT, Blankenstein MA, Oudejans CB, van Wijk IJ. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J Reprod Immunol; 59: 29 – 37, 2003.
  273. Tunca M. Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of familial Mediterranean fever. Lancet; 353: 1415, 1999.
  274. Tuzcu A, Bahceci M, Gokalp D, Tuzun Y, Gunes K. Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J, 52(1): 89 – 94, 2005.
  275. Unno N, Mitsuoka H, Uchiyama T, et al. Superficial thrombophlebitis of the lower limbs in patients with varicose veins. Surg Today; 32: 397 – 401, 2002.
  276. Vainas T, Lubbers T, Stassen FR, et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurismal tissue. Circulation; 107: 1103 – 1105, 2003.
  277. van der Merr IM, de Maat MP, Bots ML, et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol; 22: 838 – 842, 2002.
  278. Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases.J Dental Res, 82(2): 82 – 90, 2003.
  279. Varagunam M, Finney H, Trevitt R, et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis; 43: 502 – 507, 2004.
  280. Verdaet D, Dendale P, De Bacquer D, Delanghe J, Block P, De Backer G. Association between leisure time physical activity and markers of chronic inflammation related to coronary heart disease. Atherosclerosis, 176(2): 303 – 10, 2004.
  281. Vgontzas AN, Mastorakos G, Bixler EO, kales A, Gold PW, Chrousos GP. Sleep deprivation effects on the activity of the hypothalamic-pituitaryadrenal and growth axes: potential clinical implications. Clin Endocrinol (Oxf), 51: 205 – 215, 1999.
  282. Vgontzas AN, Zoumakis M, Bixler EO, Lin H-M, Follett H, Chrousos GP. Healthy young women compared to men are more resilient to sleep loss and sleep disturbance than age-matched men: potential protective role of estrogen. Program of the 85 th Annual Meeting of The Endocrine Society, Philadelphia , PA , pp 358 – 359, 2003.
  283. Vgontzas AN, Zoumakis E, Bixler EO, Lin H-M, Follett H, Kales A, and Chrousos GP. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. The Journal of Clinical Endocrinology & Metabolism, 89(5): 2119 – 2126, 2004.
  284. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults [see comments]. JAMA; 282: 2131 – 2135, 1999.
  285. Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med; 162: 2333 – 2341, 2002.
  286. Wang TJ , Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart study. Arterioscler Thromb Vasc Biol; 22: 1662 – 1667, 2002.
  287. Wells BJ, Mainous AG 3rd, Everett CJ. Association between dietary arginine and C-reactive protein. Nutrition; 21: 125 – 130, 2005.
  288. Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol; 27:2351 – 2359, 2000.
  289. Whicher JT, Chambers RE, Higginson J, Nashef L, Higgins PG. Acute phase response of serum amyloid A protein and C-reactive protein to the common cold and influenza. J Clin Pathol; 38: 312 – 316, 1985.
  290. Whicher JT, Dieppe PA. Acute phase proteins proteins. Clin Immunol Allergy; 5: 425 – 446, 1985.
  291. Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R. First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care; 26: 819 – 824, 2003.
  292. Wolfe F. The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol; 24: 1486 – 1488, 1997.
  293. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United Satates. N Engl J Med; 352: 1611 – 1613, 2005.
  294. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol; 155: 65 – 71, 2002.
  295. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology; 61: 76 – 80, 2003.
  296. Yasmin ??, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol; 24: 969 – 974, 2004.
  297. Yen – Patton GA , et al: Endothelial cell response to pulsed electromagnetic fields: stimulation of growth rate and angiogenesis in vitro. J Cell Physiol (134):1, 37 – 46, 1988.
  298. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis; 35: 469 – 476, 2000.
  299. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation; 107: 1129 – 1134, 2003.
  300. Zampelas A, Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study. Am J Clin Nutr; 80: 862 – 867, 2004.
  301. Zhao L, Zhao DM, Wei JH, Wang YQ, Huang ZM. Effect of extremely low frequency magnetic field on the focal brain injury in rats. Space Med Eng ( Beijing ), 16(1): 75 – 6, 2003.
  302. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int; 55: 648 – 658, 1999.


... página anterior

 

 

 
© 2004 Associação Brasileira de Medicina Complementar. Todos os Direitos Reservados Rua Conde de Porto Alegre , 1985 - Campo Belo
São Paulo - SP - CEP: 04608-003
Tel.: 11-5093-5685